These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography. Oka M; Matsumoto Y; Sugiyama S; Tsuruta N; Matsushima M J Med Chem; 2000 Jun; 43(12):2479-83. PubMed ID: 10882376 [TBL] [Abstract][Full Text] [Related]
5. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479 [TBL] [Abstract][Full Text] [Related]
8. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor. El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464 [TBL] [Abstract][Full Text] [Related]
9. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex. Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934 [TBL] [Abstract][Full Text] [Related]
10. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153 [TBL] [Abstract][Full Text] [Related]
14. Medical therapy in the prevention of cataract. Brown NA; Bron AJ Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085 [TBL] [Abstract][Full Text] [Related]
15. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. El-Kabbani O; Old SE; Ginell SL; Carper DA Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777 [TBL] [Abstract][Full Text] [Related]
16. Unusual binding mode of the 2S4R stereoisomer of the potent aldose reductase cyclic imide inhibitor fidarestat (2S4S) in the 15 K crystal structure of the ternary complex refined at 0.78 A resolution: implications for the inhibition mechanism. Zhao HT; Hazemann I; Mitschler A; Carbone V; Joachimiak A; Ginell S; Podjarny A; El-Kabbani O J Med Chem; 2008 Mar; 51(5):1478-81. PubMed ID: 18284183 [TBL] [Abstract][Full Text] [Related]
17. The role of the polyol pathway in diabetes mellitus. Collier A; Small M Br J Hosp Med; 1991 Jan; 45(1):38-40. PubMed ID: 1901236 [TBL] [Abstract][Full Text] [Related]
18. [Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts]. Ono H; Nozawa Y; Hayano S Nippon Ganka Gakkai Zasshi; 1982; 86(9):1343-50. PubMed ID: 6818854 [No Abstract] [Full Text] [Related]